Pembrolizumab versus paclitaxel for previously treated, advanced gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized clinical trials.

Sarya SwedNour ShaheenWael HafezNesreen Elsayed TalatSamah S RozanRehab DiabAbdulqadir Jeprel NashwanKaram R MotaweaHidar AlibrahimMhd Kutaiba AlbuniElias BattikhBisher SawafSheikh Shoib

Published in: Medicine (2022)

There is no difference between pembrolizumab and paclitaxel in objective response rate. The objective response rate shows that doctors may consider either treatment for patients with advanced gastroesophageal cancer, given the time to response is comparable across therapies.

Keyphrases

papillary thyroid
advanced non small cell lung cancer
squamous cell carcinoma
lymph node metastasis
tyrosine kinase
medical students